Hydroxycarbamide: 4 agencies, 2007–2024
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
Where hydroxycarbamide met resistance it was usually narrowed rather than refused: 3 of 7 decisive outcomes were recommendations with restrictions, against 1 outright refusal.
The file has been open for more than a decade: 16.7 years separate the first record, 7 Nov 2007 at HAS (France), from the most recent, 17 Jul 2024 at HAS (France).
AWMSG (Wales) changed its position: not recommended on 11 Oct 2010, restricted by 4 Aug 2020, after a resubmission.
No assessment is on file from PBAC (Australia), PHARMAC (New Zealand), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
Not every gap is a refusal: for hydroxycarbamide, 1 submission was never made — an outcome set by the company rather than the assessor.
3 distinct indication wordings are recorded for hydroxycarbamide by the agencies that label one in English (AWMSG and SMC).
HAS (France) was first to assess hydroxycarbamide, on 7 Nov 2007; TLV (Sweden) did not open a file until 21 Nov 2022 — an unusually long tail of 15 years between the earliest and latest system to look at it.
Restriction is doing real work here: 3 of 7 decisive outcomes narrowed hydroxycarbamide to a subgroup rather than accepting or refusing it outright, at AWMSG (Wales), SMC (Scotland) and TLV (Sweden).
3 of the 4 agencies here assessed hydroxycarbamide more than once, HAS (France) most often at 5 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 4 of the 18 agencies here have assessed hydroxycarbamide.
The full ledger for hydroxycarbamide reads 3 recommended, 3 restricted, 2 other and 1 not recommended, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 17 Jul 2024 | Change to listing conditions (Transparency Committee) | SMR substantial | source |
| TLV (Sweden) | 21 Nov 2022 | Siklos ingår i högkostnadsskyddet med begränsning | restricted subsidy | source |
| SMC (Scotland) | 10 Aug 2020 | For the prevention of vaso-occlusive complications of Sickle Cell Disease in patients over 2 years of age. | accepted (restricted) | source |
| AWMSG (Wales) | 11 Oct 2010 | Prevention of vaso-occlusive crises in patients with symptomatic sickle cell syndrome | not endorsed (non-submission) | source |
| SMC (Scotland) | 12 Oct 2009 | Prevention of recurrent painful vaso-occlusive crises | not recommended | source |
5 further decisions for hydroxycarbamide, across 2 agencies, are not shown here. They link to 3 further source documents.
Related molecules
- atezolizumab — same ATC class L01X — Antineoplastics
- olaparib — same ATC class L01X — Antineoplastics
- durvalumab — same ATC class L01X — Antineoplastics
- aflibercept — same ATC class L01X — Antineoplastics
- osimertinib — same ATC class L01X — Antineoplastics
- venetoclax — same ATC class L01X — Antineoplastics
Coverage: 10 decisions for hydroxycarbamide from 4 agencies, 2007 to 2024. Data to 7 Sep 2026. ATC class L01X — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.